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 Carbon-14, a radioactive nuclide, is used in many industrial applications.  Due to 
its wide range of uses in industry, many workers are at risk of accidental internal 
exposure to 14C.  Being a low energy beta emitter, 14C is not a significant external 
radiation hazard, but the internal consequences posed by 14C are important, especially 
because of its long half life of 5730 years [46].  The current biokinetic model 
recommended by the International Commission on Radiological Protection (ICRP) is a 
conservative estimate of how radiocarbon is treated by the human body.  The ICRP 
generic radiocarbon model consists of a single compartment representing the entire 
human body. This compartment has a biological half life of 40 days yielding an effective 
dose coefficient of 5.810-10 Sv Bq-1 [44, 45, 49, 53, 54].  This overestimates the dose of 
all radiocarbon compounds that have been studied [96]. 
 An improved model has been developed that includes and alimentary tract, a 
urinary bladder, CO2 model, and an “Other” compartment used to model systemic tissues. 
The model can be adapted to replicate any excretion curve and excretion pattern.  In 
addition, the effective dose coefficient produced by the updated model is near the mean 
effective dose coefficient of carbon compounds that have been considered in this 
research.  The major areas of improvement are: more anatomically significant, a less 
conservative dose coefficient, and the ability to manipulate the model for known 
excretion data.  Due to the wide variety of carbon compounds, it is suggested that specific 
biokinetic models be implemented for known radiocarbon substances.  If the source of 
radiocarbon is dietary, then the physiologically based model proposed by Whillans [102] 
ix 
that splits all ingested radiocarbon compounds into carbohydrates, fats, and proteins 
should be used. 
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 Carbon-14 is a long-lived radioactive nuclide with a half life of 5.73×103 years. It 
emits one beta particle per decay with an average energy of 49.5 keV [46]. Being a long-
lived beta emitter, carbon-14 is not a significant external radiation hazard, yet it presents 
a considerable threat if it becomes internally deposited within the human body. 
 Carbon is present in many forms in nature and as a product of industry.  Not only 
can carbon be found in gas, liquid, and solid state at standard temperature and pressure, 
but it is also present in various chemical forms within those states of matter. With such a 
large variation in its chemical properties and state, carbon-based compounds are treated 
in a non-uniform way by the human body. Some compounds may be totally excreted in 
the urine, while others may be totally excreted in the breath or feces. Regardless of the 
method of uptake (ingestion, inhalation, or injection/wound), the excreta pathway will 
vary from primarily fecal to primarily urine to primarily breath. This wide variation in 
excreta pathways signifies that radiocarbon compounds may have a large variation in its 
dose coefficients. 
 Much research has been performed in attempt to develop a generic model to be 
used to estimate dose following the uptake of an unknown carbon compound. The current 
widely-accepted model is the International Commission on Radiological Protection’s 
(ICRP) recommendation from ICRP Publication 30 that suggests a 40 day total body half 
life for any radiocarbon substances [44,45]. This half life was determined by performing 
a mass balance on the human body, assuming the unit-rate of carbon turnover is 
2 
equivalent to the average daily carbon intake, 0.3 kg d-1, of Reference Man [43] divided 
by the total mass of carbon in the body of reference man, 16kg. This 40 half life yields a 
dose coefficient of 5.8×10-10 Sv Bq-1 when using the ICRP 60 tissue weighting 
coefficients [50]. This dose coefficient overestimates the dose for most carbon 
compounds. For carbon monoxide, the dose is overestimated by a factor of 725 [45, 55]. 
This large overestimate of dose could result in an excessively conservative dose estimate. 
An updated generic model that represents a more “central” dose estimate should be 
considered, using scientific studies to generate the compartment model and the 
corresponding biological half-lives. 
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 A few attempts have been made to create a generic model for radiocarbon 
compounds. The initial generic radiocarbon model was created by the ICRP. In this 
model, the body is depicted as being a single well-mixed pool with a removal half-time of 
40 days. This half time is based on a balance of the carbon intake and excretion of 
Reference Man (Equation 2. 1). 
 
 
T1/2= ln 2 ×
Total mass of carbon in the body
Average daily carbon intake
 [Equation 2.1] 
 
The total body mass of carbon for Reference Man is 16 kg and the average daily carbon 
intake is 0.3 kg d-1 [43]. This yields a biological half life of 37 days, which has been 
rounded up to 40 days for radiological protection purposes. The structure of the generic 
model is displayed in Figure 2.1, where the unit biological transfer rate is presented as λ. 
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Figure 2.1 ICRP generic biokinetic model for radiocarbon labelled substances. 
 
 The generic ICRP radiocarbon biokinetic model is lacking in anatomical detail 
and tends to overestimate the dose. Much research has been performed in attempt to 
improve upon the current generic carbon model (GCM) recommended by the ICRP. A 
biochemical-based biokinetic model for the dosimetry of dietary organically bound 
tritium was developed by Richardson and Dunford [82, 83]. The form of the metabolic 
model enables the creation of a model for carbon-14. The advantage of a physiologically 
based model is that a broad range of anatomical and metabolic information can be 
incorporated. In addition, the models may be easily adjusted for people of different ages 
and genders. The model created by Richardson and Dunford, the HCNO model (able to 
model dietary H – hydrogen, C – carbon, N – nitrogen, and O – oxygen), was presented 
in a simplified version, HCNO-S, and a complex version, HCNO-C. 
λ = 1.73×10-2 d-1 
5 
 The HCNO models are based upon the overall metabolic reactions of 
carbohydrates, fats, and proteins, the building blocks of dietary substances. In the same 
manner as the ICRP GCM, the rate constants are determined via the quotient of the daily 
carbon intake by the carbon pool size. Having more compartments than the GCM, a 
carbon balance was determined for each of the compartments in the model, yet the model 
was presented for tritium, therefore the transfer rates are not available for the carbon 
version of the HCNO models. A visual representation of the HCNO-S model is displayed 
in Figure 2.2. The non-anatomical compartments in the model are carbohydrates, 
proteins, lipids, and fats. The remainder of the model is made up of ICRP models for the 
respiratory tract, gastrointestinal tract, urinary bladder, and bone compartments.  
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Figure 2.2 The HCNO-S Model proposed by Richardson and Dunford 
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 Another model attempting to describe the biokinetics of radiocarbon was created 
by Whillans [102]. The model created by Whillans shares many features with the HCNO 
models, but it is intended for intakes of organic carbon-14 and 14CO2 as opposed to 
strictly dietary carbon, as in the case of the HCNO model.  The model proposed by 
Whillans is a physiologically based biokinetic (PBBK) model, which divides all dietary 
intakes into carbohydrates, fat, and protein while including a carbon dioxide/bicarbonate 
(CO2/HCO3) pool as the central transfer compartment. The transfer rates in the model are 
based upon the nominal intakes of Reference Man and transfer rates recommended by 
Brown and Chant [8]. The structure of the PBBK model is presented in Figure 2.3. In 
Figure 2.3, Trabecular bone is TB, bone surface is BS, cortical bone is CB, carbohydrates 
are CHO, and the carbon dioxide/bicarbonate pool is CO2/HCO3. 
 The inclusion of a central bicarbonate compartment is based upon the premise that 
carbon dioxide is produced via cellular respiration, or metabolism. Regardless of the 
carbon compound entering the body, carbon dioxide may be produced as a product of 
metabolizing the compound. Bicarbonate ions, HCO3- are the main form (~80%) that 
CO2 is transported through the blood. HCO3- is formed by the enzyme carbonic 
anhydrase in the red blood cells via the reaction CO2 + H2O → H2CO3 → H+ + HCO3- 
[72]. The PBBK model proposed by Whillans improves upon the HCNO model due to 
the addition of a bicarbonate pool, yet it neglects to explicitly consider the ICRP 















 In 2009, another generic model was proposed by Galeriu et al. to describe the 
dynamic transfer of carbon-14 and tritium in mammals [27, 28]. The transfer rates in this 
model are determined by using metabolic rates, assuming the energy expenditure of a 
mammal will dictate the rate at which an internally deposited compound will be excreted 
from the body. The model is not based upon experimental data for any specific 
radiocarbon or tritiated compounds because the assumption is made by the author that 
experimental data are sparse and a more generic approach would be more resource-
effective. The primary difference between the model proposed by Galeriu et al. and the 
HCNO and PBBK models is that the transfer rates are based upon both Reference Man 




Figure 2.4 Generic radiocarbon model proposed by Galeriu 
 
 The models proposed by Galeriu et al., Richardson and Dunford, and Whillans are 
improvements upon the GCM, but their uses are restricted. The HCNO models may only 
be use for dietary radiocarbon, the PBBK model of Whillans may only be used for CO2 
and dietary carbon, and the model proposed by Galeriu may only be used dietary intakes 
and some specific chemical forms. When considering more exotic forms of radiocarbon 
such as radiopharmaceuticals, these three models may not be used. Another limitation of 
the three proposed models is the lack of experimental data to develop the models. The 
clearance rates (half-times) from the body and individual organs have been studied for 
many carbon compounds, yet the data were not considered in the development of the 
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models. A more effective generic model should be based upon experimental data for 
known carbon compounds such that the model may be used for intakes of substances 
other than strictly dietary radiocarbon. 
 The feasibility of creating a generic biokinetic model for radiocarbon was studied 
by Taylor [96]. Twenty-seven different carbon-14 labelled compounds were studied by 
Taylor to determine the biokinetic behavior. Effective doses were calculated for many 
substances that had not been analyzed dosimetrically. The dose coefficient calculations 
made by Taylor were rough estimates used for comparison with the GCM of the ICRP. It 
was determined that the GCM was a significant overestimate of the dose. Also, only 
seven of the twenty-seven compounds were retained at a level greater than 20% seven 
days after administration. This suggests that a rapid clearance is occurring, and the forty 
day half life suggested by the ICRP is an over-simplification. The compounds were 
grouped by chemical form (DNA precursors, steroid-derivatives, amino acids, glycerides, 
etc.), but similar behavior was not observed among compounds in the individual groups. 
An observation was made that the effective doses calculated for [14C]-CO2 by three 
different biokinetic models yielded doses that varied by an order of magnitude. Based 
upon this and other observations, it was concluded by Taylor that doses differing by a 
factor of less than or approximately three are not significantly different than each other 
biologically or statistically. It was recommended by Taylor that the use of the GCM 
should be reserved for situations where 14C is widely distributed throughout the 
environment and is present in the diet, and it should not be used for bioassay purposes. 
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 In order to create a biokinetic model for radiocarbon, the individual radiocarbon 
compounds were studied. As expected, many radiocarbon compounds exist as a 
byproduct of industry (14CO2 from CANDU reactors) [23], for use in medical diagnostics 
([1-14C]-glycocholic acid) [29, 33, 36], and for use in industry ([1-14C]-benzene) [9, 19, 
66, 88, 99]. Many radiocarbon compounds were considered, with the selection of 
compounds being based upon the significance of the compound and the relevant research 
available. 
 




 [1-14C]-Glycocholic acid (GCA) is used to investigate abnormal bacterial 
overgrowth or reduced resorption of bile acids in the small intestine [32]. The bond 
between the two parts of GCA, cholic acid (steroid) and glycine moiety (amino acid), is 
broken when GCA is exposed to bacterial enzymes. The [1-14C]-glycine is converted to 
14CO2, transported in the blood to the lungs, and exhaled. An increase in 14CO2 in the 
breath indicates either an increase in the amount of deconjugating microorganisms in the 
small intestine, or that bile acids are not being absorbed efficiently in the small intestine 
and are passing down to the colon, where14CO2 is produced in the bacteria-rich 
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environment, transported in the blood, and exhaled. In the normal case, the majority of 
the bile salts are returned in the conjugated form to the liver via enterohepatic circulation 
and only a minor fraction escapes absorption. 
 Gunnarsson et al. developed a model for the ingestion of [1-14C]-glycocholic acid 
consisting of three major parts [36].  One segment modeled the conjugated compound, 
another segment modeled the liberated glycine moiety, and the final segment was a 
CO2/bicarbonate pool. After ingestion, the conjugated bile acid is primarily absorbed by 
the terminal ileum during the enterohepatic cycle and becomes almost exclusively 
confined to the lumen of the biliary ducts, gut, and liver [39].  The bile acid undergoes 
enterohepatic circulation roughly six times per day. 
 Approximately 18% of the bile acid is deconjugated during each enterohepatic 
circulation, resulting in biological half life of 19h. For the normal case, a large fraction 
(46%) of the [1-14C]-glycine is transported through the intestinal tract rapidly (T1/2 = 3 h 
[11%], T1/2 = 14 h [89%]), converted to 14CO2 by the bacteria in the colon, and 
transported to the bicarbonate pool to be exhaled. The residence times in the upper large 
intestines and the lower large intestines for the fraction excreted in feces, 7.5%, are in 
accordance with the ICRP gastrointestinal model [44]. It is assumed that a significant 
fraction, 44%, of the glycine not metabolized to CO2 is transported in the blood from the 
liver, and incorporated into tissue proteins, where glycine is metabolized to CO2 by tissue 
enzymes and transferred to the bicarbonate pool, T1/2 = 6 days (70%) and T1/2 = 77 days 
(30%). The distribution of glycine within the tissue proteins should be according to 
protein contents in various organs from ICRP 23 [43]. A small fraction, 2.5%, of the 14C 
14 
is excreted in the urine according to the ICRP bladder emptying model [47]. The 

















 Xylose is a monosaccharide used for the diagnosis of abnormal intestinal bacterial 
flora. It was developed to avoid false positive results from 14C-GCA breath tests [64]. 
The advantage of xylose over GCA is that it is primarily absorbed in the proximal half of 
the small intestine, restricting the amount of xylose reaching the bacteria-rich colon. 
Xylose is mostly excreted unchanged in the urine after being absorbed in the proximal 
part of the small intestine, but if there are bacteria present in the small intestine, the 
xylose is metabolized into CO2 and ultimately exhaled [13].  Therefore, the presence of 
an abnormal amount of intestinal bacterial flora will result in an increase in the exhalation 
of 14CO2. 
 Gunnarsson et al. developed a model for the ingestion of D-[U-14C]-xylose [36]. 
Following ingestion, the xylose is transported from the stomach to the small intestines 
where a major fraction is absorbed and transported to the plasma and extra cellular fluid. 
Approximately 70% of the total xylose elimination is found in the urine (T1/2 = 2.5 h). 
The remaining 30% is eliminated via exhalation. Of this 30%, 40% is rapidly exhaled 
with T1/2 = 1.1 h (42%) and T1/2 = 3 days (58%) after being metabolized in the liver. The 
remaining 60% becomes incorporated in adipose tissue and metabolized to 14CO2 to be 
exhaled (T1/2 = 60 days). The structure of the D-[U-14C]-xylose ingestion model is shown 















 Glycerol tri[1-14C]oleate (triolein) is a triglyceride with a 14C-label on the first 
carboxyl group. When triolein reaches the intestine after ingestion, it is primarily 
hydrolyzed in the jejunum via pancreatic and intestinal lipases [81]. A small amount of 
hydrolysis also occurs in the stomach. After partial hydrolysis in the jejunum, the fat is 
introduced into the blood as chylomicrons after absorption through lymphatic vessels. A 
great amount of liberated free fatty acid is converted to 14CO2 by oxidation in the liver.  
The CO2 is eventually exhaled.  An individual with fat malabsorption will exhale a 
smaller fraction of the administered activity and excrete a larger fraction in the feces as a 
result of less free fatty acids reaching the liver [77]. 
 Gunnarsson et al. studied the biokinetics of 14C-triolien by performing breath tests 
on human subjects [35, 91, 92]. The biokinetic model used by Gunnarsson was based 
upon kinetic data from the human subjects and the ICRP model of 14C-labelled neutral fat 
[51] and is displayed in Figure 3.3. After ingestion, the triolein rapidly passes through the 
stomach into the small intestine where 70% of the 14C-triolein is transported to the liver 
following hydrolysis. In the liver, 28% of the fat compound is metabolized to 14CO2 (T1/2 
= 1 h) and transported to the bicarbonate pool.  The remaining 42% becomes 
incorporated in adipose tissue (85%) (a1=57%, T1/2 – 2 days; a2 = 43%, T1/2 = 137-620 
days), muscle (10%) (T1/2 = 2 days), and other organs (5%) (T1/2 = 137-620 days), where 
the triglycerides are oxidized and transferred to the bicarbonate pool. The kidney-bladder 
system receives 25% of the administered activity (T1/2 = 4 h). The remaining 5% of the 
19 
administered activity passes through the GI tract and is excreted in the feces according to 

















 14C urea (carbamide, H2N14CONH2) is the main end product in the human 
catabolism of proteins, polypeptides, amino acids, and other nitrogen-containing 
substances. It is water-soluble and distributes rapidly into the total body water [57, 58]. 
14C urea is used for the diagnosis of Helicobacter pylori (Hp) infection in the stomach. 
Hp bacteria produce urease, which metabolizes urea, producing CO2. In an Hp negative 
individual, the urea is rapidly absorbed unchanged into body water, not producing any 
excessive CO2.  The urea breath test is a diagnostic method to test for Hp infection by 
administering a cocktail of 14C-labelled urea to the patient orally [71]. Exhaled breath 
samples are taken 5, 10, 15, and 20 minutes after administration to determine if 14CO2 
levels are above a predefined threshold value.  
 In the normal case, 14C-urea is completely absorbed in the stomach with a half-life 
of 5 minutes. In the Hp positive case, it is assumed that 65% is immediately converted 
into 14CO2 and treated according to the dosimetric model for 14CO2/H14CO3. The 
remaining 35% are absorbed by the stomach as in the normal case.  The urea absorbed by 
the stomach is rapidly distributed in the total body water. Eighty percent of the urea in the 
total body water is excreted by the kidneys with a half-time of 6 hours, and 20% is 
rapidly dissociated in the same way as intravenously administered urea to ammonia and 
carbon dioxide and treated according to the dosimetric model for CO2/HCO3. The 

















 Travis et al. developed a model for [14C]-benzene consisting of eight 
compartments [99]. After inhalation of benzene, it is immediately deposited into a blood 
pool which exchanges activity with five compartments: adipose tissue, a muscle group, 
an organ group, bone marrow, and liver. The bone marrow and liver compartments feed a 
metabolite compartment, which is essentially a blood compartment, circulating the 
metabolites through the body. The bone marrow and liver compartments are governed by 
Michaelis-Menten kinetics such that at high concentrations of activity, the excretion via 
urine and breath is approximately equal, and at low concentrations of activity, the 
excretion via urine is approximately 90%. The water soluble metabolites empty into the 
urinary bladder after being removed from the blood by the kidneys. The transfer 
coefficients, the fractional transfer per unit time from one compartment to another, 
between compartments are presented in Table 3.1 for a case of high exposure (800 ppm 




Table 3.1 Transfer coefficients for biokinetic model for inhalation of [1-14C]-benzene. 
Compartment Transfer coefficient (d-1) 
Blood to Adipose Tissue 85.85 
Blood to Muscle Group 377.72 
Blood to Organ Group 755.45 
Blood to Bone Marrow 66.96 
Blood to Liver 429.23 
Blood to Exhaled Air 187.11 
Adipose Tissue to Blood 0.61 
Muscle Group to Blood 24.19 
Organ Group to Blood 748.25 
Bone Marrow to Blood 7.77 
Bone Marrow to Metabolite 1.78 
Liver to Blood 817.58 
Liver to Metabolite 729.42 
















 Inhaled carbon dioxide (CO2) is transferred rapidly across the alveolar membrane 
into blood [37]. Carbon dioxide is also formed in the body during the metabolism of 
organic substances. Because most of the absorbed or internally produced carbon dioxide 
is converted to bicarbonate after entering blood, data from metabolic studies involving 
intravenous injection of [14C]bicarbonate provide information on the systemic biokinetics 
of carbon inhaled as CO2.  
 Data for intravenously injected [14C]bicarbonate were used in the development of 
the model for inhaled CO2 introduced in ICRP Publications 30 [45] and applied in several 
subsequent ICRP documents on occupational or environmental intake of radionuclides.   
According to that model, inhaled carbon is rapidly and completely absorbed from the 
lungs and distributed uniformly throughout the body.  Retention, R(t), is described by the 
sum of three exponential terms: 
 
 
Rt=0.18e-0.693 t5 +0.81e-0.693 t60 +0.01e
-0.693 t
60,000  [Equation 3.1] 
 
where t is in minutes.  The first two terms are based on a two-exponential curve fit to data 
of Winchell et al. [104] on retention of 14C in 13 normal human subjects over the first 120 
min after intravenous injection with [14C]bicarbonate. The third term was added to 
represent a small component of relatively long-term retention observed in laboratory 
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animals administered 14CO2 by inhalation.  The coefficient of the third term, 0.01, is 
based on the interpretation that the two short-term components of retention identified in 
the subjects of Winchell and coworkers accounted for at least 99% of the administered 
activity.  The removal half-time associated with the third term (~40 d) is the estimated 
effective half-time for dietary carbon in a typical adult human, i.e., assuming the body’s 
carbon behaves as a single well-mixed pool.   
 ICRP Publication 80 [57, 58], which addresses doses from radiopharmaceuticals, 
describes a recycling model for 14C as carbon dioxide or bicarbonate formed in the body 
after administration of 14C-urea (Figure 3.6).  This an extension of a recycling model of 
Winchell and coworkers [104] developed from the same [14C]bicarbonate injection data 
used by the authors of ICRP Publication 30 to derive the model for inhaled carbon 
dioxide. Winchell’s model was modified by assignment of a removal half-time of 1000 h 
to Winchell’s “relatively fixed” carbon compartment, based on the long-term half-time 
used in ICRP Publication 30 (Equation 3.1) and by addition of bone compartments with 
low uptake and with removal half-times based on bone turnover.  Rates of inflow into the 
bone compartments were chosen so that realistic carbonate or bicarbonate pool sizes were 




Figure 3.6 Model for CO2/bicarbonate formed in body after intake of urea (ICRP 80) 
 
 Leggett [69] proposed a more detailed recycling biokinetic model for systemic 
radiocarbon taken into the body as carbon dioxide or bicarbonate.  Parameter values 
describing retention and excretion of activity during the first few weeks after 
administration were based on studies of the fate of radiocarbon in human subjects after 
intake of labeled bicarbonate or carbon dioxide. Data from laboratory animals given 
labeled bicarbonate, carbon dioxide, or carbonate were used to model the tissue 
distribution and the long-term retention of carbon.  The model includes a central blood 
compartment that exchanges carbon with six soft tissue compartments and five bone 
compartments representing different phases of retention as indicated by the experimental 
data. In addition to loss of label through exhalation of CO2, the model depicts small 
losses in urine and feces and through skin.  The model provides a reasonably close 
reproduction of reported biokinetic data from biokinetic studies of human subjects 
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exposed to labeled bicarbonate or carbon dioxide. The model was designed to yield 
higher total-body retention and bone retention of activity than observed in laboratory 
animals, in view of the relatively high metabolic rates and bone turnover rates in the 
studied animal species. 
 A variation of the model proposed by Leggett was applied for use in an upcoming 
ICRP report [70] to radiocarbon taken into the body as carbon dioxide or bicarbonate. 
The structure of the modified model is shown in Figure 3.7. Parameter values are listed in 
Table 3.2.  The modifications were made to bring the model into line with the generic 
modeling scheme used in this report, simplify implementation of the model by reduction 
of the total numbers of compartments and pathways, and improve the accuracy of the 
predicted urinary excretion rate at times remote from intake by including additional 
phases of transfer from soft tissues to the urinary excretion pathway.  The modified 
model adds a blood compartment (Blood 2) and pathways from soft tissues to the urinary 
bladder contents via Blood 2 that account for a delay in excretion of a portion of the 
activity appearing in urine. The modified model simplifies the original model overall by 
eliminating compartments and pathways depicting rapid exchange of activity between 
blood and peripheral compartments. Those features of the original model do not appear to 




Figure 3.7 Systemic model for carbon taken into the body as CO2/bicarbonate. 
 
 In the present model (i.e., the model defined in Figure 3.7 and Table 3.2), 
absorbed carbon is assigned to Blood 1.  Activity leaves Blood 1 at the rate 100 d-1 (T1/2 = 
10 min), with 60% of the outflow assigned to ST0, 1.8% to ST1, 0.3% to ST2, 0.44% to 
ST3, 0.15% to bone surface, 0.01% to bone volume, 36.2% to excreta through exhalation, 
0.3% to excreta via skin, 0.65% to the bladder contents, and 0.15% to the right colon 
contents. Removal half-times from ST0, ST1, ST2, and ST3 are 20 min, 0.5 d, 3 d, and 
40 d, respectively. It is assumes that 4% of outflow from ST1, ST2, and ST3 enters 
Blood 2 and all other outflow from the four soft tissue compartments returns to Blood 1.  
Activity transfers from Blood 2 to the urinary bladder contents at the rate 1000 d-1 (T1/2 = 
1 min). Based on estimates of the relative masses of Trabecular and cortical bone 
replaced per unit time in an adult human, 60% of carbon entering bone is assigned to 
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Trabecular bone and 40% is assigned to cortical bone.  The Trabecular and cortical bone 
surface compartments are assumed to lose carbon to Blood 1 with a half-time of 40 d.  
The bone volume compartments are assumed to lose carbon to Blood 1 at the rate of bone 







Table 3.2 Transfer coefficients for systemic model of carbon dioxide or bicarbonate 
From To Transfer coefficient (d-1) 
Blood 1 Excreta (exhalation) 36.2 
Blood 1 Excreta (via skin) 0.3 
Blood 1 Urinary bladder contents 0.65 
Blood 1 Right colon contents 0.15 
Blood 1 ST0 60 
Blood 1 ST1 1.8 
Blood 1 ST2 0.3 
Blood 1 ST3 0.44 
Blood 1 Trabecular bone surface 0.09 
Blood 1 Cortical bone surface 0.06 
Blood 1 Trabecular bone volume 0.006 
Blood 1 Cortical bone volume 0.004 
ST0 Blood 1 49.91 
ST1 Blood 1 1.331 
ST2 Blood 1 0.2218 
ST3 Blood 1 0.01664 
ST1 Blood 2 0.05545 
ST2 Blood 2 0.009242 
ST3 Blood 2 0.0006931 
Blood 2 Urinary bladder contents 1000 
Trabecular bone surface Blood 1 0.01733 
Cortical bone surface Blood 1 0.01733 





Total-body retention of carbon following acute input of carbon dioxide or bicarbonate 
into blood based on the present model agrees closely with predictions based on the 
original model [69].  Also, in agreement with the original model, the present model 
predicts that exhalation, urinary excretion, fecal excretion, and loss through skin accounts 
for 96.8%, 2%, 0.4%, and 0.8%, respectively, of the total loss of activity from the body 
over an extended period.  One difference in predictions of the two models is that the 
present model predicts slower accumulation of activity in bone than the original model, 
but the two models predict similar levels of activity in bone beyond a few days after acute 
input of activity to blood. For example, the present model predicts that bone contains 
0.41% of intake at 1 d, 0.36% at 10 d, and 0.098% at 100 d after intake, compared with 








 The dosimetric implications of inhaling methane gas were examined by Phipps et 
al. [80].  In the absence of other experimental information they made the conservative 
assumption that 1% of the methane was metabolized. Recent data of Carlisle et al. [10] 
suggest this to be an overestimate, and that a value of 0.1% is more likely. Dougherty et 
al. [20] estimated that approximately 0.3% of infused methane was converted to carbon 
dioxide in sheep. The available data indicate that radioactive carbon-labelled methane is 
oxidized to carbon dioxide, but the possibility of some activity being incorporated into 
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other organic molecules cannot be excluded. In an addendum to ICRP Publication 72 [55] 
a conservative assumption was made that one half of the metabolized fraction is retained 
as carbon dioxide and one half as organic carbon. The committed effective dose 
coefficient was given as 2.9E-12 Sv Bq-1 [58]. 
 




 Carbon monoxide (CO) is a potent asphyxiant at high concentrations [12]. The 
distribution and retention of [14C]-carbon monoxide has been studied extensively. Carbon 
monoxide readily diffuses across the membranes of the alveolar interstitial region of the 
lung [14]. ICRP Publication 30 [44] suggests that upon the inhalation of [14C]-CO, 0.4 is 
instantaneously bound to hemoglobin (T1/2 = 200 min) and 0.6 is instantly exhaled. 
Peterson and Stewart estimated the biological half-life of CO in the blood to be from 150 
to 200 minutes [79]. Therefore, the carbon monoxide bound to hemoglobin is assumed to 
be uniformly distributed throughout all organs and tissues and retained with a biological 
half-time of 200 minutes.  Carbon monoxide is assumed to be Class SR-1 (40% 
deposition) with Type V clearance. The corresponding effective dose coefficient 
calculated by the ICRP is 8.0E-13 Sv Bq-1 [55]. 
 
3.1.9 Other radiocarbon compounds 
 Several other radiocarbon compounds have been researched, but in less detail than 
the eight compounds already presented. A list of some other radiocarbon compounds, the 
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uptake pathway, and estimates of dose coefficients are presented in Table 3.3. Detailed 
models are not available for these compounds, therefore many assumptions were made by 







Table 3.3 The effective dose coefficients of some other radiocarbon compounds 
Compound Intake E(Sv Bq-1) 
Ba[14C]-Carbonate [65]  Inhalation 2.0E-10 
K[1-14C]-Cyanide [rat] [16] Intubation 4.6E-11 
[1-14C]-Methanol [rat] [16] IV 5.1E-11 
[2-14C]-Acetate [17] IV 4.6E-11 
[14C(U)]-Glucose [1, 24, 73] IV 2.1E-10 
[2-14C]-Glycine [5, 6, 23, 23] IV 3.3E-10 
[1-14C]-Alanine [89] IV 1.9E-10 
[4-14C]-Cholesterol [42] IV 3.0E-10 
[4-14C]-Testosterone [25,26] IV 8.2E-11 
[16-14C]-Estrone – [16-14C]-Estradiol-17β IV [2, 3, 87] 3.4E-11 
[4-14C]-Corticosterone [41] IV 9.3E-12 
[4-14C]-Cortisol [41, 76] IV 9.8E-12 








[14C]-Nitrobenzene [rat] [18] Intubation 6.3E-11 
[14C]-Delmopinol [22] Ingestion 2.9E-11 





3.2 Grouping of carbon compounds 
 The dose coefficients of the previously listed radiocarbon compounds range from 
the order of 10-13 (for carbon monoxide) to 10-10 Sv Bq-1 (for Ba-carbonate and others). 
Due to this wide variation in dose coefficients, it was considered that the compounds 
should be grouped into classes denoted by a common characteristic: dose coefficient, 
pathway of uptake, or chemical form. 
 The first type of grouping considered was a grouping by dose coefficient. A 
scatter plot ranking the carbon compounds by dose coefficient was created (Figure 3.8), 
but carbon monoxide, methane, and carbon dioxide, three well-known carbon gasses are 

































To determine if the carbon compounds within these three groups share common 
biokinetic or chemical traits, the compounds from “Group 2” (3.4E-11 to 1E-10 Sv Bq-1) 
were studied. The compounds in group two did not share a common path of uptake and 
do not share a common chemical form. For example, [1-14C]-urea is studied for the case 
of ingestion, but [4-14C]-testosterone is studied for the case of injection. [4-14C]-cortisol 
is a steroid-derivative, and [14C]-xylose is a monosaccharide. The compounds in Group 2 
are not similar on a biokinetic basis either. [16-14C]-estrone-[16-14C]-estradiol-17β has 
a retention of approximately 20% a week following prompt intake while [14C]-
nitrobenzene has a retention of approximately 6% a week after intake. Group 1 and 
Group 3 were also studied, and they did not share any biokinetic or chemical traits. 
 Since no similarities were reveal by sorting the compounds, the pathway of 
uptake and the chemical forms should be considered as a possible trait that may 
determine how the human body treats a radiocarbon compound. Considering only the 
inhaled compounds, the dose coefficient fluctuates from a low value of 8.0E-13 Sv Bq-1 
to a high value of 2.0E-10 Sv Bq-1 for Ba[14C]-carbonate, a factor of 4,000 difference. 
The manner by which the compound is deposited in the body is not a determining factor 
of the dose coefficient or biokinetics considering such a large variation in dose 
coefficients. 
 The final category by which the compounds were sorted in attempt to expose 
similar biokinetics was chemical characteristics. Taylor has already attempted to sort the 
most studied radiocarbon compounds using this approach, but it was not successful. An 
example of a chemical grouping used by Taylor [96] is presented in Table 3.4. The dose 
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coefficient varies from a value of 9.3E-12 to 4.0E-10 Sv Bq-1 and the retention at 7 days 
ranges from 55% to less than 10%. 
 
Table 3.4 Retention and Dose Coefficients of some radiocarbon steroid-derivatives 
Compound Intake Retention at 7d (%) E (Sv Bq-1) 
[4-14C]-cholesterol IV ~55 3.0E-10 
[1-14C]-glycocholic acid Ingestion ~35 4.0E-10 
[4-14C]-testosterone IV <20 8.2E-11 
[16-14C]-estrone-[16-14C]-estradiol-17β IV <20 4.5E-11 
[4-14C]-corticosterone IV ~10 9.3E-12 
[4-14C]-cortisol IV <10 9.8E-12 
 
 Similar biokinetic behaviors were not uncovered by any of the attempts at 
grouping the compounds by common characteristics. The inability to reveal similar 
biokinetic behaviors by organizing the compounds into groups is a product of the wide 
variety of radiocarbon-containing compounds. 
 
3.3 Generic radiocarbon model development 
 
 The manner in which radiocarbon compounds are processed by the human body is 
dictated by the chemical form of the radiocarbon. With various chemical forms of carbon 
in existence, the biokinetics of the radiocarbon varies greatly among all compounds. 
Excretion data and common anatomical characteristics were the primary source of 
information used in the development of an improved generic radiocarbon model. 
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3.3.1 Development of Model Structure 
 
 The three major pathways of excretion for the radiocarbon compounds considered 
in this paper are breath (exhalation), urine, and feces.  For the compounds in Table 3.3, 
the urinary excretion ranges from 1 to 100% (rounded average of 60%), the breath 
excretion ranges from 0 to 95% (rounded average of 25%), and the fecal excretion ranges 
from 0 to 99% (rounded average of 15%).  According to Taylor [95, 97], the pathway of 
excretion and the rate at which a compound is eliminated from the human body have a 
correlation to the dose coefficient. Therefore, the large range in the effective dose 
coefficients for the compounds in Table 3.3 are a product of the widely varying excretion 
pathways. 
 The excretion of radiocarbon from the human body can be described by a 3 – or 
less – component exponential with a major short term component, an intermediate 
component, and a long term component. The GCM of the ICRP has a single component 
elimination, which is described by a one component exponential elimination rate. In order 
to account for the muli-half-life excretion rate, multiple compartments are necessary. To 
determine these compartments, common anatomical features and excretion data were 
observed from the previously developed models. 
 The organs through which the compounds pass vary among all compounds. Some 
compounds may pass through the liver or gall bladder while others may not.  A 
compartment that it utilized frequently in biokinetic modeling for combining many 
organs into one “pool” is the “Other” compartment. All organs besides those pre-defined 
by a biokinetic model are accounted for in the “Other” compartment.  For modeling a 
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generic radiocarbon-containing substance, the “Other” compartment would be useful 
because the affected organs vary for each compound, and the “Other” compartment will 
represent the organs that are different for each compound (liver, kidneys, spleen, etc.). 
The disadvantage of using an “Other” compartment is that the model will not be as 
physiologically accurate modeling the manner in which the human body processes an 
intake of radiocarbon. For this reason, it is discouraged to use a compartment that 
generalizes an organ or tissue, such as the “Other” compartment, when modeling specific 
compounds. But for creating a generic model, the encapsulating nature of the “Other” 
compartment is preferred because it will be able to represent any organ that may be 
burdened by the chemical after it is deposited within the human body. 
 When considering any carbon substance, carbon dioxide must be considered 
because of its vital role in critical biochemical processes. CO2 is a critical component in 
cellular respiration and pH regulation within the human body. According to the Bohr 
effect, as the amount of carbon dioxide increases, more H+ are formed and the pH will 
decrease. Therefore, a lower pH in the blood is often the product of increased carbon 
dioxide concentration.  The increase in carbon dioxide concentration also suggests that a 
tissue is more active and requires more oxygen.  As a response, the smooth muscles will 
dilate to increase oxygen flow to the muscles because of the increase in carbon dioxide 
concentration, making carbon dioxide a negative regulator of smooth muscle dilation. 
This is also observed in the lungs. When alveolar CO2 levels are low, the smooth muscle 
will constrict, but if CO2 levels are high, the smooth muscle will dilate. 
 The biokinetic models presented in sections 3.1.1-3.1.5 and 3.1.7 all contain a 
carbon dioxide pool because of the production of CO2 as a metabolic side-product of 
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processing the compound. In addition, models for glycine and some of the models 
proposed for dietary carbon also contain a CO2 compartment.  Due to the vital role of 
CO2 in the human body metabolism and the consideration of CO2 in previous radiocarbon 
models, a CO2 compartment was considered in the development of a generic model.   
 Another common feature in many carbon models is the long term retention of 
radiocarbon in the adipose tissue. To represent the long term component of the 
elimination of carbon from the human body, many models divert a portion of the 
internalized radiocarbon to an adipose tissue compartment that represents long term 
retention. It was mentioned by Richardson [86] that the difference in carbon-14 doses 
between men and women is due to the carbon saturation in adipose tissue, and in the 
current ICRP dosimetric construct, the activity burden in adipose tissue is “lost dose.”  A 
few examples of models that consider adipose tissue for long term retention of 
radiocarbon are glycocholic acid, xylose, triolein, methanol (rat study), and cyanide (rat 
study). The adipose tissue compartment will represent the long term retention component 
that is expressed in many radiocarbon excretion data. A half-life of 100 days was given to 
the adipose tissue compartment, based upon a rounded average of the available data. 
 In addition, an alimentary tract must be considered. All ingested substances or 
inhaled particulates will be swallowed and deposited in the alimentary tract beginning 
with the stomach, proceeding to the small intestines, and finally the colon to be excreted 
as feces. The alimentary tract used in the generic model is based upon the ICRP 30 GI 
model [45], but with the upper large intestines and lower large intestines combined into a 
single “Colon” compartment so that the model may be used with the updated version of 
the Human Alimentary Tract Model (HATM).  The small intestines of the alimentary 
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tract will exchange with the blood, and may be deposited into the Other compartment, 
which may represent the liver and gall bladder.  This transfer may be related to the 
transfer that occurs between the small intestines and the liver via the hepatic portal vein. 
Upon leaving the Other compartment, a portion may be metabolized, creating 14CO2 as a 
by-product, or it may circulate into the Colon, enterohepatic circulation, to be ultimately 
excreted into the feces. 
 The final element of the generic model that must be considered is the kidney-
bladder component. For this generic model, the kidneys are accounted for in the Other 
compartment, therefore only a urinary bladder is necessary. The kidney-bladder model is 
based upon the model presented in ICRP 53 [47]. The source which feeds the kidneys and 
urinary bladder is a blood pool. The blood pool is the main transfer compartment that 
feeds the urinary bladder and other compartments. The fractional excretion and rate of 
excretion are highly dependent upon the transfer rates to and from the blood 
compartment.  The manner in which those transfer rates were chosen will be discussed in 
the section 3.4. The generic model structure is presented in Figure 3.9. The “Other” and 
“Adipose Tissue” compartments are represented in the figure as “Systemic Tissue (Short 
Term)” and “Systemic Tissue (Long Term)” respectively. The reason for renaming the 
compartments in this manner is so that the dosimetric considerations of the tissues could 
be altered according to the preferences of the user. For instance, the short term systemic 
tissue may be modeled as “Other” and the long term may be modeled as “Adipose 
Tissue,” but if a higher, more conservative effective dose coefficient is wanted, the long 
term compartment may be modeled as “Other,” as well. The dosimetric implications of 
the tissue choices will be considered in section 3.4. 
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For the case of ingestion, the compound is deposited in the stomach and is treated 
according to the ICRP gastrointestinal model with an f1 value of 0.99. The portion of the 
compound in the blood pool is transported to the urinary bladder to be excreted as urine 
and to the “Other” compartment. The Other compartment metabolizes a portion of the 
compound to CO2 to be deposited into the bicarbonate pool, transports a portion of the 
compound to the lower large intestines, and transports a final portion back into the blood 
pool. The portion which is transported into the Colon will be further processed and 
excreted as feces. The portion deposited in the bicarbonate pool will be treated according 
to the CO2/bicarbonate model developed by Leggett. 
For the case of inhalation, the compound enters the human respiratory tract model 
(HRTM) and is transported to the stomach and blood pool to be treated as described 
above [52, 60]. 
If a radiocarbon compound is introduced into the body via a wound or intravenous 












The transfer coefficients in Figure 3.9 not previously defined are: Blood to 
Systemic (Short), Blood to Urinary Bladder, Systemic (Short) to Blood, Systemic (Short) 
to CO2, Systemic (Short) to ULI, and Blood to Systemic (Long). The rate of excretion 
and the excretion pattern (fraction in feces, urine, and breath) are dictated by these 
systemic tissue transfer coefficients.  The urinary excretion rates for some of the 
compounds in Table 3.3 are listed in Table 3.5. The fecal and breath excretion rates are 
not readily available for a significant portion of the compounds in Table 3.3, therefore 
only the renal excretion profile can be considered.  If more data become available for 
fecal and breath excretion, the model can be further improved. 
 
 
Table 3.5 Urinary excretion rates for various carbon compounds 
Chemical Form Half Life 1 Half Life 2 Half Life 3 
Barium Carbonate 1. d 5. d 
Cyanide 0.4 d 2.5 d 33. d 
Methanol 0.6 d 7. d 75. d 
Glycine 0.26 d 2.5 d 53. d 
Testosterone 1. d 6.25 d  
Estrone and estradiol 1. d   
Corticosterone 0.08 d 5. d  
Cortisol 0.15 d 0.92 d  
Inulin 0.07 d   
Delmopinol 0.08 d 0.5 d  
Dexloxiglumide 0.08 d 0.29 d  
Average 0.43 d 3.2 d 53.67 d 
 
 
Other excretion information is available for total excretion, and, according to Leggett, 
may also be used for renal excretion data.  The average half-time was 0.43 d (range 0.07-
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1.0 d) for the fastest phase, 3.3 d (range, 0.29-7.0 d) for the intermediate phase, and 100 d 
(range 33-620 d).  The fast phase typically represented 85% or more and the intermediate 
component about 5% of total urinary excretion. 
 
3.3.2 Determining transfer and effective dose coefficients for generic model 
 
 Currently the most commonly used biokinetic modeling application is Dose and 
Risk Calculation Software (DCAL), which is available from the EPA or from the ORNL 
Center for Biokinetic and Dosimetric research websites [21].  DCAL is useful for 
determining the activity in organs over time for various radionuclides introduced into the 
human body via various forms of intake (ACTACAL module). It is also useful for 
determining the dose coefficients for the same cases considered by the ACTACAL 
module, using a combination of SEECAL (calculates the specific effective energies), 
EPACAL (calculates dose rates), and HTAB (tabulates the total effective dose coefficient 
and organ-specific dose coefficients). DCAL can be used by advanced users to 
implement user-created models for the calculation of the activity as a function of time, 
cumulative excretion, and effective dose coefficients. 
 The general procedure of implementing a model in DCAL is by modifying a .DEF 
file. An example of the .DEF file used for this generic carbon model to represent an 
average excretion rate/profile is presented in Appendix A.  After creating or modifying a 
.DEF file, the DCAL module window is opened, and it is confirmed that the DCAL 
module is working in the same directory as the .DEF file location.  To begin the 
ACTACAL module, the “Activity as f(t)” option must be selected by the user.  A series 
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of questions are asked such as the nuclide name, the uptake pathway, and other options 
such as the age of the individual being exposed to the radiation. For the generic carbon 
model, it was always assumed that the individual was 7300 days old, or an adult.  The 
child and younger cases could not be considered because of insufficient data. After the 
ACTACAL module has been run, a .ACT file will have been created in the working 
directory, containing the data for the activity as a function of time in all organs affected 
by the compound being considered. For cumulative excretion, the BIOTAB module can 
be implemented from the main module, but only the 24 hour urinary and fecal excretions 
are tabulated. For most case, this is sufficient, but for the case of this generic model 
development, more excretion information was needed, and it was calculated via 
integration, using the .ACT file as the data source. 
 Biokinetic models can be viewed mathematically as a system of first-order 
differential equations. This relatively complex system of differential equations is replaced 
with a relatively simple mathematically formulated estimation by the differential equation 
solver used in DCAL. It is assumed that the system may be estimated by linear 
differential equations over many time intervals or “time steps.” Specifically, each 
compartment is isolated and it is assumed that the rate of change in activity in the 
compartment can be described by the sum of a constant inflow rate of P and an outflow 
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 [Equation 3.2] 
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The solution for this differential equation is: 
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	 [Equation 3.3] 
 
The integrated activity from time 0 to time T is: 
 







	  [Equation 3.4] 
 
For recycling models such as the generic carbon model being proposed, these equations 
to not directly apply.  Therefore, the solution for these compartments is determined by 
applying these equations iteratively until a solution with the desired accuracy is achieved.  
 In order to determine the transfer coefficients that would yield a urinary excretion 
profile similar to the available renal excretion data, a .DEF file was implemented using 
the previously defined transfer coefficients and best guesses for the unknown transfer 
coefficients.  After the ACTACAL module was implemented on the .DEF file, the 
resulting .ACT file was manipulated to determine the cumulative urinary excretion over 
time, the cumulative fecal excretion, and cumulative breath excretion.  The urinary 
excretion curve from the .ACT file was compared to a multiple scatter plot of the 
available excretion data.  Adjustments were made to the unknown transfer coefficients in 
attempt to produce a more central average excretion curve. This process was repeated 
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many times, and due to its inefficient nature, other means of iterating on the unknown 
transfer coefficients to match the average urinary excretion curve were investigated. 
 The differential equation solver from Mathematica [105] was considered for 
solving the system of differential equations in a more efficient manner than DCAL [4]. 
Mathematica is a computational software program used in scientific, engineering, and 
mathematical fields. A system of differential equations can be solved quickly and easily 
using the NDSolve method from Mathematica. The means by which systems of 
differential equations are solved by NDSolve are not known because the module is 
proprietary. The step size is automatically adapted by NDSolve so that the estimated error 
in the solution is within predefined tolerances. Specifically, the precision is set to 9 
decimal places. 
 In addition to NDSolve, another method contained in Mathematica that is useful 
for determining the unknown transfer coefficients in a more efficient process is the 
Manipulate command. An equation passed into the Manipulate method can be altered by 
varying any of the variables that the user would want to manipulate. For the case of 
solving this differential equation, the six unknown transfer coefficients were able to be 
manipulated while dynamically solving the system of differential equations using 
NDSolve. The commands that were used to solve a more simple set of differential 
equations for the case of injecting radiocarbon directly into the blood is presented in 
Appendix B.  The resulting interface that is generated by the Manipulate command is 












The ranges on each of the sliders were predefined in the original command from 
Appendix B. By sliding a specific slider from left to right, the transfer coefficient will 
increase. Sliding right to left will decrease the transfer coefficient. In order to determine 
the specific value of the transfer coefficient, the plus symbol on the right side of the slider 
can be activated to reveal a text box containing the current value of the transfer 
coefficient. The values of the transfer coefficients may also be manipulated using text 
input in the text box that is activated after clicking the plus symbol. 
 The Manipulate and NDSolve commands, alone, are not sufficient to aid in 
solving of the unknown transfer coefficients. In order to receive feedback on how an 
increase or decrease in the value of a transfer coefficient may affect the urinary excretion 
curve, the urinary excretion over a period of 100 days was dynamically plotted. 
Therefore, a chart was generated with two separate plots: a scatter plot of all the available 
excretion data normalized to the same total excretion and the urinary excretion curve 
produced by the model. Real-time, user-controlled curve fitting was able to be conducted 
so that the user could determine how the urinary excretion curve would change while 
altering the transfer coefficients. An example of how increasing the Blood to Urinary 
bladder transfer coefficient affects the urinary excretion curve is presented in Figure 3.11. 
In Figure 3.11, the scattered data is a plot of all the available excretion data being used as 
a benchmark and the solid line is the transforming urinary excretion curve produced by 
the model. When the transfer coefficient is increased in part B of Figure 3.11, the 
beginning portion of the curve increases dramatically due to an increase in the early 






Figure 3.11 The effect of increasing the Blood to Urinary Bladder transfer coefficient. 
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 Iteratively manipulating the transfer coefficients and viewing the effects of the 
manipulations, a reasonable urinary excretion fit was obtained. The corresponding 
urinary excretion curve is presented in Figure 3.12, where the dashed line is the 
benchmark excretion curve and the solid line is the model-generated urinary excretion 
curve. Note that the asymptotic excretion value is 0.6, which is the total urinary excretion 
fraction using the average generic case. In addition to fitting the urinary excretion curve, 
the proper excretion fractions were also fit simultaneously such that the excretion at 500 














 After manipulating the transfer coefficients, it was apparent that each transfer 
coefficient affected different regions of the curve. The slope of the beginning of the curve 
(approximately 0 to 0.5 days for this case) was affected by the Blood to Urinary Bladder 
transfer coefficient; the slope of the next part of the curve from 0.5 to 2 days was altered 
using the Blood to Systemic (Short) transfer coefficient; the coefficient of the middle of 
the curve from 2 to approximately 20 days was affected by the Systemic (Short) to Blood 
transfer coefficient; and the final part of the curve was affected by the Systemic (Short) to 
Feces, Systemic (Short) to Breath, and Blood to Systemic (Long) transfer coefficients.  
The transfer coefficients used in the generic model for the average case are presented in 
Table 3.6.  Many other transfer coefficients are used in the generic model to describe the 
transfer to and from other compartments. These may be referenced in Appendix A. 
 
Table 3.6 Transfer coefficients used in the generic model 
Compartment Transfer coefficient (d-1) 
Systemic (Short) to CO2 Model 0.062 
Systemic (Short) to Blood 0.093 
Systemic (Short) to Colon 0.037 
Blood to Systemic (Short) 1.27 
Blood to Bladder 1.51 
Blood to Systemic (Long) 0.276 
 
 
 For the case of ingested radiocarbon, activity moves through the alimentary tract 
as described in the Human Alimentary Tract Model and is nearly completely (99%) 
absorbed to blood from the small intestine contents (SI).  Blood loses activity with a half 
life of 5 hours, with 50% of the outflow assigned to the urinary bladder contents; 40% to 
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the short-term systemic compartment, and 10% to the long-term compartment. The short-
term systemic tissue compartment loses activity with a half life of 3 days.  Outflow from 
this compartment is divided as follows: 40% returns to Blood, 30% is secreted into the 
colon contents and subsequently excreted in feces, and 30% moves to blood compartment 
in the carbon dioxide model (Figure 8).  Carbon entering the long-term retention 
compartment is assumed to be metabolized slowly to carbon dioxide, which moves to the 
blood compartment of the carbon dioxide model with a half-time of 100 d. A curve 
representing the total body retention as a fraction of initial uptake via injection is 
presented in Figure 3.13, comparing the updated model to the ICRP 71 GCM.  The GCM 
retains more activity in the beginning, yet it drops of faster than the updated model after a 
period of approximately 500 days. This is due to the long term retention of the “Systemic 
Tissue (Long)” (or Adipose Tissue) compartment and the bone compartments from the 
CO2 model. Not only is the ICRP model too conservative in its dose coefficient, it is also 
not conservative enough about the total body retention after a period of 500 days. 











 The single compartment, 40 day half-life, model currently being used by the ICRP 
for generic radiocarbon does not resemble the multiple half life excretion rate that is 
observed for many compounds in literature. A comparison between the urinary excretion 
from the 40 day model and the excretion observed in experimental studies is displayed in 
Figure 3.14. Not only is the excretion not the same general shape as the other excretion 
curves, but it is also much lower. None of the excretion data represent a lower excretion 
than the generic carbon model at any time period. The reason is because the first, fast half 
life observed in all radiocarbon excretion is never greater than 1 day, while in the GCM, 












 After determining the transfer coefficients, a .DEF file was updated with the 
correct transfer coefficients so that DCAL could be used to calculate the effective dose 
coefficient. Using ACTACAL, SEECAL, EPACAL, and HTAB, the total effective dose 
coefficient was tabulated as 110-10 Sv Bq-1 for the case of injection, when using the 
tissue weighting coefficients of ICRP 60 [50]. This dose coefficient is near the geometric 
mean, 1.2110-10 Sv Bq-1, of the dose coefficients for the radiocarbon compounds 
considered in Table 3.3 of this research. If more conservatism is wanted, and Systemic 
(Long) is modeled as “Other,” an effective dose coefficient of 2.4×10-10 Sv Bq-1 is given. 
These effective dose coefficients are considerably lower than the previous generic 
radiocarbon model that yielded an effective dose coefficient of 5.80E-10 Sv Bq-1 [45]. 
 Perhaps a less convoluted way of comparing the models is a comparison of the 
cumulative activity. The effective doses depend on tissue weighting coefficients, tissue 
specifications, and other arbitrary factors that convolute the comparison. DCAL can be 
used to determine the U50 values which are the number of nuclear transformations 
occurring in the body over 50 years. A few carbon compounds were chosen for 
comparison against the generic model and the ICRP 40 day model. The compounds were 
chosen because they represent both high and low effective dose coefficients. A 
comparison of U50 values are presented in   
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Table 3.7.  The updated generic model is conservative in all cases besides xylose, which 
has a rather high effective dose coefficient. For other compounds with high effective dose 
coefficients such as glycocholic acid and triolein, the cumulative activity is comparable. 
The U50 data for each compartment of the updated generic model are presented in Table 
3.8 for the case of injection.  The compartment with the most nuclear transformations is 
the Systemic Tissues (Long) compartment followed by the Systemic Tissues (Short) 
compartment. The compartments with the least cumulative activity were the Cortical 




Table 3.7 Relative U50 values for some carbon compounds 
Model 
Relative U50 (Nuclear 
transformation expressed as a 
multiple of the U50 value 
predicted by the updated 
generic carbon model) 
Updated Generic Carbon Model 1 
Benzene 0.03 





Generic Model in ICRP Publication 71 3 
 
 
Table 3.8 U50 values for the compartments of the updated model 
Region U50 (total nuclear transformations per Bq of intake) 
Blood 3.6E4 
Systemic Tissue (Short) 2.5E5 
Urinary Bladder Contents 4.5E3 
Systemic Tissue (Long) 1.4E6 
Colon Contents 1.4E4 
Trabecular Bone Surface 3.4E3 
Cortical Bone Surface 2.2E3 
Trabecular Bone Volume 7.9E3 
Cortical Bone Volume 2.4E4 
Total Retained 1.8E6 
 
 
 This improved generic carbon model can be easily adapted to properly model 
numerous excretion patterns or rates. If more excretion data become available in future 
research, the model can be adapted to consider the updated excretion information. Also, if 
bioassay data is available, the model can be transformed to simulate the actual excretion 
profile for an individual to obtain a more accurate dose assessment. The generic 
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radiocarbon model suggested in this research is an improvement over the ICRP generic 
radiocarbon model because it is dynamic and more physiologically acceptable. 
 
3.4 Recommendation for dosimetric treatment of radiocarbon 
 
 The manner in which the human body treats a radiocarbon substance is not 
dictated by the presence of radiocarbon, but rather the chemical form of the radiocarbon 
substance.  Based upon this fact, the multiple ways in which the human body processes 
radiocarbon substances are as numerous as the number of radiocarbon substances in 
existence. Therefore, it is recommended that, if the radiocarbon substance is known, the 
specific biokinetic models and effective dose coefficients associated with that substance 
be used for dosimetric assessment. The established biokinetic models for specific 
radiocarbon compounds have been presented for eight substances in earlier sections of 
this document. 
 If the radiocarbon substance is not known, yet it is certain that an individual has 
taken up radiocarbon, it is suggested that the revised generic carbon model be used to for 
dosimetric assessment and setting dose limits. Currently, the ICRP suggests that in the 
latter case, a one-compartment whole body model be used with a 40 day half life. The 
updated generic model suggested in this paper is superior to the ICRP generic carbon 
model because it is more anatomically accurate, containing an alimentary tract, kidney 
bladder model, CO2 model, an adipose compartment, and an “other” compartment for 
modeling systemic tissues. Also, the improved generic radiocarbon model is dynamic. It 
may be adapted to fit any excretion data that may become available in future research or 
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in a bioassay of someone exposed to radiocarbon. The updated generic model is able to 
match the urinary excretion data much better than the 40 day ICRP model because of its 
many components. The single exponential excretion of the ICRP 40 day model, although 
conservative, does not resemble the actual excretion data. 
 The final case that must be considered for radiocarbon uptake is dietary uptake.  
For this specific instance, it is suggested that the models proposed by Whillans or 
Richardson should be used. The model by Whillans is the superior model of the two 
because transfer coefficients were presented along with the model structure, while the 
model proposed by Richardson only presents the model structure. The transfer 
coefficients used in the Whillans dietary carbon model are based upon Reference man 
values and transfer coefficient suggested by Brown and Chant.  The tissue weighting 
coefficients that are to be used in either of those models are not thoroughly explained, 
therefore the judgment of the user must be used to determine how to represent the 
tissues.. 
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CHAPTER 4:  CONCLUSIONS 
 
 When comparing the 5.810-10 Sv Bq-1 effective dose coefficient produced by 
ICRP 71, 40-day-half-life, generic model to the effective dose coefficients of individual 
carbon compounds, it is apparent that the model greatly overestimates dose.  The 
overestimate ranges up to a factor of 725 for carbon monoxide, and it is more than a 
factor of 9.2 greater than the median dose coefficient for the carbon compounds 
considered in Table 3.3 of this paper.  The generic carbon model is also not 
representative of how the human body treats radiocarbon substances taken up by the 
human body.  Most radiocarbon substances are expelled at a rate that is represented by 
multiple half lives, while the generic model is only a single half life. 
 The radiocarbon model proposed in this research improves in multiple areas over 
the current ICRP recommended model.  The effective dose coefficients, 110-10 Sv Bq-1 
for modelling slow turnover as adipose and 2.4×10-10 Sv Bq-1 for modelling slow 
turnover as “Other,” are near the geometric mean for the compounds listed in Table 3.3, 
1.2110-11 Sv Bq-1.  They are both within a factor of 3 for uncertainty of dose 
coefficients from biokinetic models that was discussed by Taylor.  The model is more 
anatomically appropriate, including an alimentary tract, urinary bladder, and a model for 
metabolic production of CO2.  Perhaps the most attractive feature of the updated generic 
model is the adaptability.  The only transfer coefficients that are fixed in the model are 
ones based upon pre-defined ICRP models. For instance, the GI tract transfer coefficients 
are based upon the ICRP 30 model, yet if the ICRP generates an updated GI tract model, 
the generic carbon model will be able to evolve and implement the updated GI tract 
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model. The six transfer rates that are not based upon predefined ICRP standards can be 
evaluated using excretion data. If more research on the excretion of radiocarbon 
compounds from the human body emerges, the model can be adapted to account for the 
new data.  Also, the model can be adapted to match excretion data for unknown 
radiocarbon compounds from bioassay. 
 For the case of not knowing the chemical form of the radiocarbon taken up by an 
individual, the generic model is suggested; but if the radiocarbon compound taken up by 
an individual is known, the specific biokinetic models for that compound should be 
implemented.  If the uptake of radiocarbon is from dietary sources, the model proposed 
by Whillans should be used for dosimetric assessment considering it is the most fully 
developed dietary carbon model available. 
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CHAPTER 5:  FUTURE WORK 
 
 To develop a better radiocarbon biokinetic model, more excretion data are 
needed.  The limiting condition in this research was the inability to conduct radiocarbon 
studies for any radiocarbon compound of interest.  Therefore, the data used in this 
research were only available from previously studies on C14-labelled substances. Only 
urinary excretion data were available for many compounds, while breath and fecal 
excretion were only available for a few compounds and could not be used as a benchmark 
for creating the model. When more studies are performed on radiocarbon in the future, 
this model should be updated to reflect the newly available data. 
 Another potential improvement that can be made towards modeling radiocarbon is 
dietary carbon model development.  The uptake of radiocarbon in food and drink is a 
significant concern, and the behavior of dietary carbon is different than the behavior of 
other forms of radiocarbon.  Dietary carbon is expected to behave in the same manner as 
all nutrients entering the human body, being split into carbohydrates, fats, and protein 
prior to being fully metabolized.  A comprehensive model of dietary radiocarbon should 
be created and tested against any dietary carbon data that is available for humans.  The 
model created by Whillans was not thoroughly tested against experimental data, and no 
dietary radiocarbon model has been fully tested and explicitly defined (tissue weighting 
factors, transfer coefficients, etc.). There is a lack of dietary radiocarbon excretion data in 
the research, so future studies in dietary radiocarbon may require animal studies or 
epidemiological studies of populations that have ingested dietary radiocarbon (if they 
exist). 
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 Ultimately, it would be ideal if each radiocarbon compound could be treated with 
a specific model for that compound, but determining the chemical form is not always a 
feasible, therefore a generic model will be required unless if the chemical form of the 
radiocarbon can be determined upon excretion.  More research should be done on 
radiocarbon compounds that are not well known, but may be encountered in the 
workplace or environmental settings. 
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APPENDIX A: .DEF FILE USED IN DCAL FOR GENERIC 
RADIOCARBON 
The .DEF file below uses Muscle for the Systemic Tissue (Long) compartment.  
Generic model for carbon 




 7300 Adult 
Blood     ->Other_5    1.2700E+00 
Blood     ->UB_Cont    1.5100E+00 
Blood     ->Muscle     2.7600E-01 
Other_5   ->Blood      9.3000E-02 
Other_5   ->Blood_1    6.2000E-02 
Other_5   ->ULI_Cont   3.7000E-02 
Muscle    ->Blood_1    6.9300E-03 
Blood_1   ->Excreta    3.6500E+01 
Blood_1   ->Other_1    6.0000E+01 
Blood_1   ->Other_2    1.8000E+00 
Blood_1   ->Other_3    3.0000E-01 
Blood_1   ->Other_4    4.4000E-01 
Blood_1   ->T_Bone-S   9.0000E-02 
Blood_1   ->C_Bone-S   6.0000E-02 
Blood_1   ->T_Bone-V   6.0000E-03 
Blood_1   ->C_Bone-V   4.0000E-03 
Blood_1   ->UB_Cont    6.5000E-01 
Blood_1   ->ULI_Cont   1.5000E-01 
Other_1   ->Blood_1    4.9910E+01 
Other_2   ->Blood_1    1.3310E+00 
Other_3   ->Blood_1    2.2180E-01 
Other_4   ->Blood_1    1.6640E-02 
Other_2   ->Blood_2    5.5450E-02 
Other_3   ->Blood_2    9.2420E-03 
Other_4   ->Blood_2    6.9310E-04 
T_Bone-S  ->Blood_1    1.7330E-02 
C_Bone-S  ->Blood_1    1.7330E-02 
T_Bone-V  ->Blood_1    4.9320E-04 
C_Bone-V  ->Blood_1    8.2190E-05 
Blood_2   ->UB_Cont    1.0000E+03 
EOF Data 
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Compartment Abbreviation Compartment Description 
St_Cont Stomach Contents 
SI_Cont Small Intestines Contents 
ULI_Cont Upper Large Intestines Contents 
Other_4 The main other compartment 
Blood _2 CO2 model blood pool 
Blood Non-CO2 blood 
UB_Cont Urinary Bladder Contents 
Excreta Exhaled CO2 
Other_1 1st Other compartment in CO2 model 
Other_2 2nd Other compartment in CO2 model 
Other_3 3rd Other compartment in CO2 model 
T_Bone-S Trabecular Bone Surface 
C_Bone-S Cortical Bone Surface 
T_Bone-V_1 Trabecular Bone Volume 1 
C_Bone-V_1 Cortical Bone Volume 1 
T_Bone-V_2 Trabecular Bone Volume 2 




APPENDIX B: MATHEMATICA CODE 
 This section is composed of Mathematica code used to solve a system of 
differential equations for the simple case of injection in the revised generic radiocarbon 
model. The Manipulate and NDSolve commands are used in the first section to create a 
box with “sliders” used to manipulate specified variables and solve the system of 
differential equations respectively. Following the “slider” graphic, the Plot command 
dynamically plots the urine excretion while the sliders are used to change the value of a 
transfer coefficient. Also, three numbers are displayed dynamically: the total urine 
excretion, fecal excretion, and breath excretion. 
 
Excreta =  








s = NDSolve[{ 
qblood'[t] == -(BloodtoUB + BloodtoOther + 
BloodtoAdiposeTissue) * qblood[t] + OthertoBlood * 
qother[t], 
qother'[t] == BloodtoOther * qblood[t] - (OthertoBlood 
+ OthertoColon + OthertoCO2) qother[t] , 
qcolon'[t] == OthertoColon * qother[t] – 1 * 
qcolon[t], 
qfeces'[t] == 1 * qcolon[t], 
qco2'[t] == OthertoCO2 * qother[t] + 0.01 * 
qadipose[t], 
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qubladder'[t] == BloodtoUB * qblood[t] – 12 * 
qubladder[t], 
qadipose'[t] == BloodtoAdiposeTissue * qblood[t] - 
0.01 * qadipose[t], 
qurin'[t] == 12 * qubladder[t], 
qblood[0] == 1, 
qother[0] == 0, 
qcolon[0] == 0, 
qfeces[0] == 0, 
qco2[0] == 0, 
qubladder[0] == 0, 
qadipose[0] == 0, 
qurin[0] == 0 
    }, {qblood, qother, qcolon, qfeces, qco2, qubladder, 
qadipose, qurin}, {t, 500}]} 
, {BloodtoUB, .05, 5}, {BloodtoOther, .01, 5}, 
{BloodtoAdiposeTissue, 0.01, 2}, {OthertoBlood, .01, 3}, 







{Show[Plot[{Evaluate[qurin[t] /. s]}, {t, 0, 100},  
PlotStyle -> {Black, {Thick, Black}}, 
PlotRange -> {0, 1},  
Frame -> True,  
FrameLabel -> {"Time (days)", "Urinary Excretion per 
unit intake"}, 
LabelStyle -> {Large}],  
ListPlot[Excreta, PlotStyle -> {Thin, Black}, 
PlotMarkers -> {\[EmptySmallCircle]}]],  
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A GENERIC BIOKINETIC MODEL FOR CARBON-14 
R. P. Manger 
Oak Ridge National Laboratory, 545 Oak Ridge Turnpike, Oak Ridge, TN 37830, USA 
The generic biokinetic model currently recommended by the ICRP for the 
treatment of systemic radiocarbon assumes uniform distribution of activity in 
tissues and a biological half-time of 40 d.  This model is intended to generate 
cautiously high estimates of dose per unit intake of C-14 and, in fact, generally 
predicts a much higher effective dose than systemic models that have been 
developed on the basis of biokinetic studies of specific carbon compounds. The 
simplistic model formulation precludes its application as a bioassay model or 
adjustment to fit case-specific bioassay data. This paper proposes a new generic 
biokinetic model for systemic radiocarbon that is less conservative than the current 
ICRP model but maintains sufficient conservatism to overestimate the effective dose 
coefficients generated by most radiocarbon-compound-specific models. The 
proposed model includes two systemic pools with different biological half-times 
representing an initial systemic form of absorbed radiocarbon, a submodel 
describing the behaviour of labelled carbon dioxide produced in vivo, and three 
excretion pathways: breath, urine, and faeces.  Generic excretion rates along each 
path are based on multi-phase excretion curves observed in experimental studies of 
radiocarbon.  The generic model structure is designed so that the user may adjust 
the level of dosimetric conservatism to fit the information at hand and may adjust 
parameter values for consistency with subject-specific or site-specific bioassay data. 
 
INTRODUCTION 
Many biokinetic models exist for specific carbon-14-containing compounds, yet due to 
the large amount of radiocarbon substances, more forms of radiocarbon have not been 
modelled. The biokinetics of systemic radiocarbon is dependent on the carbon compound 
taken into the body and the location of the radioactive atom within the molecule(1). 
Internally deposited 14C-labelled compounds have residence time ranging from a few 
hours(2) to several months(3). The distribution of radiocarbon in the body and the pathway 
of excretion are also dependant on the chemical properties of the carbon compound taken 
84 
into the body. In a study by Taylor(1), it was determined that the effective dose 
coefficients for different internally deposited, 14C-labelled compounds vary over at least 
three orders of magnitude. 
The International Commission on Radiological Protection (ICRP) provides compound-
specific models for radiocarbon compounds such as carbon monoxide, carbon dioxide, 
methane, and inulin. For other radiocarbon compounds that do not have a specific model, 
the ICRP recommends a dosimetrically cautious model. This generic model was first 
recommended in ICRP Publication 30(4) for the treatment of 14C-labelled compounds that 
have been inhaled or ingested. The recommended use of the generic model is for either 
the uptake of an unknown radiocarbon compound or the uptake of a form of radiocarbon 
without a predefined biokinetic model. The generic model is based upon the average rate 
of carbon intake for Reference Man(5) and the total mass of carbon in the body of 
Reference Man(5). Using 16 kg for the total body mass of carbon in and 0.3 kg d-1 for the 
average daily carbon intake, a half life of approximately 40 days is calculated. In ICRP 
Publication 68(6) and 71(7), it was assumed that carbon is instantaneously and uniformly 
distributed in the body tissue and excreted with a half time of 40 days. An effective dose 
coefficient of 5.8×10-10 Sv Bq-1 for inhaled or ingested C-14 was calculated by the ICRP 
using this model and assuming rapid and virtually complete absorption to blood. 
The effective dose coefficients for most carbon compounds that have been researched 
appear to be greatly overestimated by the ICRP generic radiocarbon model based on 
comparison with dose coefficients generated by available carbon-compound-specific 
models(1). The purpose of this paper is to propose a new generic systemic biokinetic 
model for carbon-14 that may be used for the assessment of internal exposure to 
radiocarbon compounds in the workplace. The intended use of this model is for situations 
where either the form of the internally deposited 14C is unknown or the biokinetics of that 
form of carbon has not been established. 
An effort has been made to include the major paths of movement and the major pathways 
of excretion for most carbon compounds deposited in the body so that the model can be 
adjusted on the basis of case-specific data to improve dose estimates for specific cases. 
For instance, adjustments may be made to the model to alter the rate at which the carbon 
is excreted from the body or the pathways of radiocarbon excretion. 
The proposed model is less conservative than the ICRP Publication 71 generic model 
for carbon, but it also accounts for the possible long term retention of radiocarbon in the 
body. Compared to the effective dose coefficients of some of the specific forms of 
radiocarbon that have been studied, the proposed model is still more likely to 
overestimate than underestimate dose per unit intake of 14C in the workplace. If it is 
suspected that the model may underestimate the tissue doses or effective dose, the 
transfer coefficients may be modified to yield a longer retention time than the baseline 
values provided in this paper. 
In this paper, some of the current radiocarbon models are presented along with their 
experimental excretion data and model characteristics. An updated generic model is then 
proposed and compared to some of the current radiocarbon models. In addition, examples 
are given to show how the transfer coefficients may be modified for improved dose 
estimates when case-specific information is available. 
CURRENT RADIOCARBON MODELS 
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Many radiocarbon biokinetic models have been developed for specific radiocarbon 
compounds. The manner in which radiocarbon compounds are processed by the human 
body is dictated by the chemical form of the radiocarbon. Excretion data and common 
anatomical characteristics were the primary source of information used in the 
development of the generic radiocarbon model proposed here. 
Excretion Data 
Excretion data are available for many of the carbon compounds that have been studied. 
Specifically, the urinary excretion data are available for most compounds in literature, 
while the breath excretion, faecal excretion, and plasma concentration data are less 
frequently specified. 
The urinary excretion of the radiocarbon compounds that were considered in this 
research are described by a three – or less – component exponential. The excretion for the 
ICRP generic carbon model is described by a single, 40 day, exponential elimination. 
More compartments are required to model the fast, moderate, and slow components of 
elimination that are not being considered by the single compartment elimination of the 
ICRP 71 model. 
The excretion characteristics vary among all chemical forms of radiocarbon. For 
compounds with available excretion data, the cumulative urinary excretion ranges from a 
factor of 0.01 to 1 of the total radiocarbon taken up; the cumulative faecal excretion 
ranges from a factor of 0 to 0.99 of the total radiocarbon taken up; and the cumulative 
breath excretion ranges from 0 to 0.95 of the total radiocarbon taken up. On average, the 
excretion profile was approximately 60% urinary, 25% exhaled, and 15% faecal. The 
compounds upon which these data are based are: K[1-14C]-cyanide(8), [1-14C]-methanol(9), 
[14C(U)]-glucose(10, 11), [2-14C]-glycine(12, 13), [4-14C]-cholesterol(3), [4-14C]-testosterone(14, 
15), [16-14C]-estrone – [16-14C]-estradiol-17β(16), [4-14C]-corticosterone(17), [4-14C]-
cortisol(18), [2-14C]-thymidine(19), [14C]-inulin(2, 20), [2-acetate-14C]-
diethylenetriaminepenta acetate (DTPA)(21), [14C]-nitrobenzene(22), [14C]delmopinol(23),  
and [14C]dexloxiglumide(24). Of those compounds, cyanide and methanol were studied in 
rats, and the other listed compounds were studied in human subjects. 
The typical elimination rates also varied from compounds such as inulin with a single 
component half life of 1.67 h to compounds such as methanol with 85% leaving at a half 
life of 0.6 days, 10% leaving at a half life of 7 days, and 5% leaving at a half life of 75 
days. The reported urinary excretion rates consisted of up to three components: a fast 
component, intermediate component, and slow component.  The average biological half-
time of the fast phase was approximately 0.4 days (range 0.07 – 1.0 d), the intermediate 
phase was approximately 3 days (range 0.29 – 7 d), and the slow phase was 
approximately 70 days (range 33 – 620 d). 
Characteristics of published models for inhaled forms of carbon 
Biokinetic models have been implemented for many radiocarbon compounds. Due to the 
assortment of chemical forms of radiocarbon, the model structures vary among all 
compounds, but the models share a few common characteristics. 
Glycocholic acid, xylose, triolein, and urea were studied by Gunnarsson, Leide-
Svegborn, et al.(26-36) Each of these models shares the common feature of having an 
integrated CO2 model. Models such as the biokinetic model describing methane(20), the 
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model proposed by Whillans for dietary carbon(25), the model for glycine-2-14C(12, 13), and 
others also feature an integrated CO2 model. CO2 is an important compound in the human 
body due to its critical role in cellular respiration and pH regulation within the human 
body. 
Another common feature in many carbon models is the long term retention of 
radiocarbon in the adipose tissue. To represent the long term component of elimination 
and the tendency of radiocarbon to slowly metabolize with adipose tissue, a portion of the 
internalized. radiocarbon is deposited in an adipose tissue compartment thatrepresents 
long term retention in several of the previous biokinetic models. A few examples of 
models that considered long term retention of radiocarbon in adipose tissue are models 
for glycocholic acid(34), xylose(34), triolein(35), methanol (based on a rat study)(9), and 
cyanide (based on a rat study)(9). 
Other systemic compartments and their half-times vary among the available 
radiocarbon biokinetic models. In certain models, the liver is an important component, 
while other models do not consider the liver. The same is true for the kidneys, gall 
bladder, and other tissues. For the generic case, an “Other” compartment may be used to 
represent this category of tissues. The details of how this may be accomplished are 
included in the description of the generic model. 
Characteristics of dietary carbon models 
 In a model proposed by Richardson and Dunford(32, 83), dietary carbon entering the 
body is divided into carbohydrates, lipids, and proteins. Simple and complex versions of 
the biokinetic model are proposed.  The complex version divides carbohydrates into 
glucose and glycogen, lipids into fatty acids and adipose fat, and protein into amino acids 
and soft tissue proteins. The model is intended for use with hydrogen (3H), carbon (14C), 
nitrogen (15N), and oxygen (18O) radionuclides. Transfer coefficients and effective dose 
coefficients were not presented by Richardson and Dunford for 14C substances. 
A model proposed by Whillans(25) also separates all dietary carbon into carbohydrates, 
fats, and proteins. A central CO2/bicarbonate compartment is supplied by these three 
components. The CO2 compartment also exchanges activity with some bone 
compartments. All three excretion pathways (urinary, fecal, and breath) are present. The 
model was also presented with radiocarbon-specific transfer coefficients. The transfer 
coefficients were based upon intakes by Reference Man(5) and suggestions by Brown and 
Chant(34). 
A third model proposed for the intake of dietary carbon was developed by Galeriu et 
al(28). This model uses anatomical compartments and transfer coefficients determined 
from reference physiological constants such as metabolic rates, body energy densities, 
and empty body masses. The transfer coefficients were developed for various farm 
animals, but using the same method, transfer coefficients could be developed for human 
beings. 
DESCRIPTION OF THE PROPOSED GENERIC MODEL 
The generic 14C model proposed in this paper is based upon common (but not universal) 
characteristics of current biokinetic models and excretion data derived from biokinetic 
studies on human subjects or rats. The model accounts for the short, moderate, and long 
half times that are present in many of the radiocarbon compounds that have been studied. 
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The pathways of intake considered are inhalation, excretion, and injection/wound. The 
pathways of excretion considered are renal, faecal, and exhaled. The structure of the 
model is presented in Figure 1. Upon ingestion, the radiocarbon proceeds according to 
the Human Alimentary Tract Model (HATM)(36). Radiocarbon reaching the contents of 
the small intestines is nearly completely absorbed to blood (99%). In the baseline case the 
blood pool has a half life of approximately 5 hours. C-14 reaching the blood is transferred 
to the urinary bladder contents (50%), a systemic tissue compartment to be processed at a 
moderate rate (T1/2 = 3 days) (40%), and another systemic tissue compartment to be 
processed at a slower rate (T1/2 = 70 days) (10%). The systemic tissue compartment with 
a faster metabolic rate represents systemic tissues other than adipose tissue, while the 
slower metabolic compartment represents long term retention in adipose tissue. 
Approximately 40% of the activity entering the moderate systemic tissue compartment 
is transferred back to the blood, 30% is metabolized to carbon dioxide, and the final 30% 
is secreted into the contents of the colon to be excreted as faeces. The longer lived 
systemic tissue compartment slowly metabolizes the radiocarbon to carbon dioxide. The 
radiocarbon entering the carbon dioxide compartment is treated according to a simplified 
version of the CO2/bicarbonate model proposed by Leggett(37). The CO2/bicarbonate 
model was modified to simplify implementation of the model by reducing the total 
number of compartments and pathways, to make the model more consistent with the 
scheme of the updated generic model, and to improve predictions of the long-term 
urinary excretion rate by including additional phases of transfer from soft tissues to the 
urinary excretion pathway1. Transfer coefficients for the modified CO2 model (Figure 2) 
are presented in Table 1(38). Activity entering the CO2 model is deposited in the Blood 1 
compartment. 
Inhaled radiocarbon is treated according to the Human Respiratory Tract Model 
(HRTM)(39) to be absorbed in the blood and swallowed to the alimentary tract. The 
activity entering the blood is treated in the same manner as the radiocarbon that reaches 
the blood via the small intestines contents, while the activity entering the alimentary tract 
is treated according to the HATM. 
Transfer coefficients for the systemic portion of the model were determined by using 
the NDSolve and Manipulate commands in Mathematica, Version 7.0(40), which allows 
for dynamic numeric differential equation solving. The urine excretion data were 
available for many radiocarbon compounds. The renal excretion over time was plotted for 
each compound by normalizing the maximum cumulative urinary excretion. Meanwhile, 
a curve representing the urinary excretion of the model in Figure 1 was displayed on the 
same graphic so that the change in the shape of the urinary excretion curve could be 
viewed as the transfer coefficients were adjusted using Manipulate and NDSolve. The 
transfer coefficients were fine-tuned until the urinary excretion curve represented a 
central fit of all the urinary excretion rate data (Figure 3).The ideal fit was represented by 
a blood half time of 5 hours, and two systemic half times of 3 days and 70 days, which is 
on the same order as the available urinary excretion data for radiocarbon compounds. In 
addition, the average excretion profile (60% in urine, 25% in breath, and 15% in faeces) 
was used as a benchmark for the fine-tuning of the transfer coefficients. The final transfer 
coefficients that were calculated using the described methods are presented in Table 2. 
                                                 
1 Personal communication from R. Leggett, Oak Ridge National Laboratory, Oak Ridge, TN 37830. 
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The model is dynamic because the systemic transfer coefficients may be adjusted to 
compensate for specific cases. For instance, if the urinary excretion were higher, the 
fraction being transferred to the systemic tissues could be decreased accordingly. The 
half times of either or both systemic tissue compartments could be increased if more 
conservatism is wanted. The transfer coefficients presented in Table 2 represent a slightly 
conservative estimate of the average radiocarbon compound. 
COMPARISON WITH OTHER MODELS 
The effective dose coefficient calculated for this model varies according to how the 
system compartments are treated. If the moderate systemic compartment is modelled as 
“Other,” and the slow systemic compartment is modelled as “Adipose Tissue,” the dose 
coefficient is approximately 1×10-10 Sv Bq-1 when using ICRP 60(41) tissue weighting 
factors for the case of injection. If both compartments are modelled as “Other,” the dose 
coefficient is approximately 2.4×10-10 Sv Bq-1 when using ICRP 60 tissue weighting 
factors for the case of injection. This is a factor of about 2.5 to 6 less than the dose 
coefficient calculated using the ICRP generic radiocarbon model. All dose coefficient 
calculations were computed using Dose and Risk Calculation Software (DCAL), Version 
9.0(42). 
A less convoluted relationship is a comparison of the cumulative activity in the body 
over time. Using DCAL, the U50 values – number of nuclear transformations at 50 years 
– were calculated for some low and high effective dose coefficient compounds and are 
presented in Table 3. It can be observed when comparing the U50 data with other 
compounds that the generic carbon model is of the same order or greater than the other 
models. Therefore the proposed generic 14C model, although less conservative, is still 
conservative when compared to most radiocarbon compounds on a cumulative activity 
basis. 
A comparison of the urinary excretion from the modified generic radiocarbon model 
and the ICRP 71 generic carbon model is presented in Figure 4. The excretion of the 40 
day model was normalized to 60% urinary excretion for comparison with the modified 
generic model and urinary excretion from previous radiocarbon studies. The excretion of 
the 40 day model greatly lags the observed excretion and the updated model excretion 
over the first 100 days. The whole body retention of the updated model and the 40 day 
model are displayed in Figure 5. Up until approximately 500 days, the 40 day model lags 
the model presented in this paper. After 500 days, the 40 day model retains less than 
predicted by the updated model because of the longer half lives of the bone compartments 
in the CO2 model and the adipose tissue/systemic tissue (long) compartment. 
MODIFICATION FOR SPECIFIC CASES 
In practice, the radiocarbon model presented in this paper may be manipulated on a case-
by-case basis. One instance in which manipulation of the model may be necessary is for 
the case of a radiocarbon compound that is known to be excreted at a different rate or 
with a different excreta allocation than the generic case. Another example in which the 
model may be changed is for an unknown radiocarbon compound that is not being 
excreted at the same rate or with the same excreta distribution predicted by the generic 
carbon model. An additional instance that may require manipulation of parameter values 
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is if inadequate information about the radiocarbon compound has been collected and 
more conservatism is wanted. 
An example of a radiocarbon compound with an excretion rate that is greater than the 
generic case is DTPA. Intravenously injected DTPA is excreted from the body quickly, 
with half-times of approximately 1.4 minutes (~60%), 14.3 minutes (~20%), and 95 
minutes (~20%)(21). These half times are much shorter than the half-times associated with 
the transfer coefficients in Table 2. In addition, nearly all of the DTPA is excreted in the 
urine as opposed to the 60% assumed in the average case. Adjusting the half-times of the 
systemic compartments in Figure 1 and iteratively solving the differential equations using 
Manipulate and NDSolve in Mathematica, a new set of transfer coefficients may be 
determined for DTPA. The Blood to Urinary Bladder transfer coefficient is increased to 
approximately 70 d-1, which is associated with a half-time of approximately 14 minutes. 
The Systemic Short to Blood transfer coefficient is increased to 10 d-1, the Blood to 
Systemic Short transfer coefficient is decreased to 0.7 d-1, and the Blood to Systemic 
Long transfer coefficient is decreased to 0.1 d-1. By altering the half-times of these 
components, the three-component excretion of DTPA is able to be modelled. 
For the case of an unknown radiocarbon substance that has been internally deposited, 
the average case (Table 2) may be used, but if the observed bioassay data are not similar 
to what is predicted by the average case, the half-times can be altered to match the 
unknown compound. For instance, if the excretion rate of an unknown radiocarbon 
substance is approximately the same as the average case, but the pathway of excretion is 
different, the model may be altered to fit that case. If the excretion is 20% in urine, 20% 
in breath, and 60% in faeces, a new set of transfer coefficients can be determined to 
match this differing excretion pattern. For this case, Blood to Urinary Bladder is 
decreased to 0.35 d-1 and Systemic Short to Colon is increased to 0.95 d-1. Altering these 
two half times changes the excretion profile to 60% in faeces, 20% in breath, and 20% in 
urine. 
The final instance where manipulation of the average case may be necessary is when 
more conservatism is wanted. For this case, the half times of the systemic compartments 
can be increased, which will yield much lower transfer coefficient, a higher number of 
nuclear transformations in the body, and a higher effective dose coefficient. The 
magnitude of the increased conservatism is determined by how much longer the half-
times are adjusted. 
Alterations to the generic model are complex due to the recycling portion of the model. 
As a result, a simple formula cannot be applied to easily manipulate the excretion rate or 
excretion pathways. The differential equations must be solved to determine the excretion 
curve and the excretion fractions. In this paper, Mathematica was used, but other 
resources are also available to iteratively solve the systems of differential equations so 
that the proper alterations may be prepared. 
SUMMARY 
The generic radiocarbon model that has been proposed is different than the ICRP generic 
carbon model for a few distinct reasons. The model is less conservative than the 40 day 
half-life model, but still maintains enough conservatism to have an effective dose 
coefficient greater than the majority of radiocarbon compounds with known effective 
dose coefficients. Also, the model contains a respiratory tract, alimentary tract, and two 
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systemic compartments as opposed to the single 40 day half-life compartment. By having 
more compartments, the time rate of excreta resembles the multi-phase excretion curves 
observed in experimental studies of radiocarbon. The model is dynamic having the ability 
to emulate a specific retention profile. It may also be adjusted to be more or less 
conservative. The model presented in this paper is reasonably consistent with the 
experimental data available on radiocarbon and models human excretion data more 
precisely than the ICRP 40 day half life model. For dietary carbon, the models developed 
by Whillans(25) and Richardson and Dunford(32, 83) are promising for the internal 
dosimetry of radiocarbon taken up in the human diet. 
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Table 1. Transfer coefficients for the modified CO2 model used in conjunction with 
the updated generic radiocarbon model.a 
Path Transfer Coefficient (d-1) 
Blood 1 to Excreta (exhalation) 36.2 
Blood 1 to Excreta (via skin) 0.3 
Blood 1 to Urinary bladder contents 0.65 
Blood 1 to Colon contents 0.15 
Blood 1 to Soft tissue 0 60 
Blood 1 to Soft tissue 1 1.8 
Blood 1 to Soft tissue 2 0.3 
Blood 1 to Soft tissue 3 0.44 
Blood 1 to Trabecular bone surface 0.09 
Blood 1 to Cortical bone surface  0.06 
Blood 1 to Trabecular bone volume 0.006 
Blood 1 to Cortical bone volume 0.004 
Soft tissue 0 to Blood 1 49.91 
Soft tissue 1 to Blood 1 1.331 
Soft tissue 2 to Blood 1 0.2218 
Soft tissue 3 to Blood 1 0.01664 
Soft tissue 1 to Blood 2 0.05545 
Soft tissue 2 to Blood 2 0.009242 
Soft tissue 3 to Blood 2 0.0006931 
Blood 2 to Urinary bladder contents 1000 
Trabecular bone surface to Blood 1 0.01733 
Cortical bone surface to Blood 1 0.01733 
Trabecular bone volume to Blood 1 0.0004932 
Cortical bone volume to Blood 1 0.00008219 




Table 2. Baseline transfer coefficients for the systemic compartments of the generic 
radiocarbon model. 
Path Transfer Coefficient (d-1) 
Systemic (Short) to CO2 Model 0.062 
Systemic (Short) to Blood 0.095 
Systemic (Short) to Colon 0.070 
Systemic (Long) to CO2 Model 0.0099 
Blood to Systemic (Short) 1.27 
Blood to Bladder 1.51 
Blood to Systemic (Long) 0.276 
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Table 3. Comparison of cumulative activity in the body for carbon-14 labelled 
substances. 
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Figure 1. Model structure of the proposed generic radiocarbon biokinetic model. 
Figure 2. Model structure of the modified CO2/bicarbonate biokinetic model. 
Figure 3. Urinary excretion rates, based upon exponential fits,  for many radiocarbon 
compounds. The central line in a fit to the experimental data. 
Figure 4. Urinary excretion curves for the ICRP 71 40 day model, the modified generic 
carbon model presented in this paper, and previously studied radiocarbon compounds. 
Figure 5. Total body retention of the ICRP 71 model and the modified generic carbon 
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